Applying Glycobiology To Develop Novel Medicines
About
IHP Therapeutics is applying Glycobiology to develop novel medicines. Glycobiology is an emerging field of research and drug development, with potential for treating multiple diseases.
IHP-100 compounds are novel small molecule glycan therapeutics which inhibit selectin and complement activity. These compounds have the potential to: (i) enable gene therapy by modulating immune response to viral vector administration and (ii) inhibit cancer metastasis through selectin inhibition.
IHP’s clinical-stage compound, IHP-009, is a glycan NCE (New Chemical Entity) with anti-inflammatory, antiviral, and anticoagulant activity. Clinical planning is underway for dosing hospitalized ARDS (Acute Respiratory Distress Syndrome) patients with IHP-009. This clinical study may also include patients infected with SARS-CoV-2.
Mission
To improve and save lives through scientific discovery and development of glycan therapeutics.
Our Team
Rinko Ghosh, MS, MBA
CEO
Jocelyn Jackson
Acting CFO
Peggy McLaughlin
VP of Clinical Operations
Gabriel Njikang, PhD
Director of CMC Project Mgmt
John Paderi, PhD
Chief Science Officer
Kate Stuart, PhD
VP of Program Management
Robert Van Gorp
VP of Strategic Sourcing
Board of Directors
Rinko Ghosh, MS, MBA
Vlad Hogenhuis, MD, MBA
John Paderi, PhD
Clinical and Scientific Advisors
Science
IHP Therapeutics is building on nearly a century of clinical and basic science research with glycan-based compounds to create the next generation of glyco-medicines to treat diseases with significant unmet need. We are developing both novel pipeline compounds, such as IHP-100, as well as clinical-stage IHP-009, a new chemical entity with an established clinical safety profile. Our goal is to translate the therapeutic potential of these glycan compounds into clinically significant benefits for patient.